Tresiba Flextouch U-100 (Insulin Degludec) — Medicare Part D spending
Novo Nordisk · Rank #73 by total Part D spend · CMS data year 2023
Medicare Part D spent $726,928,549 on Tresiba Flextouch U-100 (Insulin Degludec) in 2023, the #73 drug by total Part D spending out of 3,598 drugs. That worked out to about $35.94 per dosage unit, $727 per claim and $2,813 per beneficiary, across 1,000,189 claims for 258,451 beneficiaries. Average spending per dosage unit rose +0.9% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Tresiba Flextouch U-100 (Insulin Degludec) spending at a glance (2023)
| Metric | Tresiba Flextouch U-100 (Insulin Degludec) |
|---|---|
| Total Part D spending (2023) | $726,928,549 |
| Total spending (2022) | $669,375,559 |
| Year-over-year change in total spending | +8.6% |
| Average spending per dosage unit (2023) | $35.94 |
| Change in spend per dosage unit (YoY) | +0.9% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +1.2% |
| Average spending per claim (2023) | $727 |
| Average spending per beneficiary (2023) | $2,813 |
| Total claims (2023) | 1,000,189 |
| Beneficiaries (2023) | 258,451 |
| Total dosage units (2023) | 20,224,379 |
| Manufacturer(s) | Novo Nordisk |
| National rank by total spend (of 3,598 drugs) | #73 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $669,375,559 | $726,928,549 | +8.6% |
| Avg spend per dosage unit | $35.61 | $35.94 | +0.9% |
| Avg spend per claim | $709 | $727 | — |
| Avg spend per beneficiary | $2,863 | $2,813 | — |
| Total claims | 943,973 | 1,000,189 | — |
| Beneficiaries | 233,827 | 258,451 | — |
How Tresiba Flextouch U-100 compares with nearby drugs
Drugs with total Part D spending closest to Tresiba Flextouch U-100 (Insulin Degludec):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Tresiba Flextouch U-100 (Insulin Degludec) (this drug, #73) | $726,928,549 | $35.94 | +0.9% |
| Verzenio (Abemaciclib) (#71) | $756,850,867 | $275.07 | +6.3% |
| Lantus (Insulin Glargine,Hum.Rec.Anlog) (#72) | $735,735,411 | $29.55 | +4.3% |
| Abrysvo (Rsv Vacc, Pref A And Pref B/PF) (#74) | $698,160,178 | $327.30 | — |
| Lumigan (Bimatoprost) (#75) | $697,002,199 | $99.66 | +5.8% |
| Brilinta (Ticagrelor) (#76) | $691,725,954 | $7.64 | +3.9% |
Frequently asked questions
How much does Medicare Part D spend on Tresiba Flextouch U-100?
Medicare Part D spent $726,928,549 on Tresiba Flextouch U-100 (Insulin Degludec) in 2023 (the latest CMS data year), across 1,000,189 claims for 258,451 beneficiaries. That ranks #73 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Tresiba Flextouch U-100?
In 2023, the weighted average Medicare Part D spending per dosage unit for Tresiba Flextouch U-100 (Insulin Degludec) was $35.94. Compared with 2022 it rose +0.9%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Tresiba Flextouch U-100?
CMS attributes Tresiba Flextouch U-100 (Insulin Degludec) to Novo Nordisk in the 2023 Part D spending file. Average spending per claim was $727 and per beneficiary $2,813.
Is the Tresiba Flextouch U-100 figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20